Form 4: PMV Pharma CEO Exercises Stock Options
Insider Transaction Report
PMV Pharmaceuticals President and CEO, David Henry Mack, exercised options to acquire 220,643 shares of common stock at $1.37 per share.
Summary
- David Henry Mack, President and CEO of PMV Pharmaceuticals, Inc., exercised employee stock options on October 27, 2025.
- Acquired 220,643 shares of common stock at an exercise price of $1.37 per share.
- The transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged trading plan.
- Following the transaction, Mack directly owns 451,109 shares and indirectly owns 675,867 shares through various trusts.
- The exercised options were fully vested and immediately exercisable, with an expiration date of November 16, 2026.
Sentiment
Score: 7
Explanation: The exercise of stock options by a CEO is generally viewed as a positive signal, indicating management's confidence in the company's future value. The transaction being under a Rule 10b5-1 plan is a neutral to positive factor for compliance and transparency.
Positives
- CEO David Henry Mack exercised a significant number of stock options (220,643 shares), which can be interpreted as a signal of confidence in the company's future prospects.
- The transaction was conducted under a Rule 10b5-1 plan, which demonstrates a pre-planned approach to trading and helps mitigate concerns about opportunistic insider trading.
Future Outlook
This Form 4 filing, which reports an insider transaction, does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing is a company-specific insider transaction report and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: The exercise of options by the CEO could be perceived as a positive indicator of management's belief in the company's stock, potentially influencing investor sentiment.
Key Dates
| Date | Description |
|---|---|
| August 13, 2025 | Re-registration of 305,667 shares from direct ownership to the Mack-Mulligan Revocable Trust. |
| October 27, 2025 | Date of employee stock option exercise. |
| October 29, 2025 | Date Form 4 was signed by power of attorney. |
| November 16, 2026 | Expiration date of the exercised employee stock options. |
Keywords
PMV Pharmaceuticals, PMVP, David Henry Mack, Stock Option Exercise, Insider Transaction, Form 4, CEO, Equity, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.